THE COUNCIL FOR TOBACCO RESEARCH – U.S.A., INC.

CONFIDENTIAL REPORT

SCIENTIFIC ADVISORY BOARD MEETING

NEW YORK, NEW YORK

OCTOBER 10-11-12, 1973

Dr. Sheldon C. Sommers, Chairman	
Dr. Howard B. Andervont	
Dr. Richard J. Bing	
Dr. William U. Gardner	Scientific Director, CTR
Dr. Robert J. Huebner	
Dr. Leon O. Jacobson (10/10-11)	
Dr. Hans Meier	
Dr. John P. Wyatt	
Dr. Helmut R. R. Wakeham	Chairman, ITC
Mr. H. H. Ramm	President, CTR
Mr. W. T. Hoyt	Executive Vice President, CTR
Dr. Robert C. Hockett	Research Director, CTR
Dr. John H. Kreisher	Associate Research Director, CTR
Dr. Frederic W. Nordsiek	Associate Research Director, CTR
Dr. Vincent F. Lisanti (10/10-11)	Research Associate, CTR
Mr. Leonard S. Zahn	Consultant, CTR

The Chairman opened the meeting and reviewed changes in the composition of the staff and the Board since its last meeting. He noted that Dr. William U. Gardner's appointment as Scientific Director had become effective on July 1, 1973 and that on the same date Dr. Robert C. Hockett, who had been Acting Scientific Director, was appointed Research Director. Also that Drs. Cattell and Loosli had resigned from the Board and that Dr. Lynch had assumed the role of a Board member emeritus.

The Scientific Director advised that Dr. Averill A. Liebow, Professor and Chairman, Department of Pathology, at the University of California, San Diego, had agreed to join the Board, and that three other scientists were under consideration

1. The report of the meeting of the Scientific Advisory Board, held on March 14-15-16, 1973, was approved.

2. The report, actions, and recommendations of the June 13, 1973 meeting of the Executive Committee of the Scientific Advisory Board were approved and amended to authorize the staff to approve 776-AM, Elliot S. Vesell, M.D. up to an amount of $34,730.00 less the $8,500.00 previously approved by the Executive Committee (776-A) provided that Dr. Vesell provides a satisfactory report of progress and a modified application for continuation.

1003545088

Source: https://www.industrydocuments.ucsf.edu/docs/zjdm0000

3. The following administrative actions were approved:

381R2 Barbara B. Brown, Ph.D. A balance of $2,248.75 remained after completion of this project and is therefore cancelled.

547-CR1 Joseph J. Guarneri, Ph.D. Permission was granted to carry forward the unexpended balance of $1,578.43 to 547-CR2.

550-AMR2 John E. Craighead, M.D. An unexpended balance of $584.62 was received and deposited.

603-AR2 Shirley L. Kauffman, M.D. Permission was granted to carry forward the unexpended balance of $3,835.44 to 603-B.

603-B Permission was granted to extend this project from September 30 to December 31, 1973.

623-BR1 Walter B. Essman, Ph.D. A balance remained of $450.00 after completion of this project and is therefore cancelled.

688-A Sheldon C. Sommers, M.D. An unexpended balance of $11,202.98 was received and deposited.

702 Albert H. Niden, M.D. Through an administrative error the final quarter of this grant was not paid and, therefore, a check in the amount of $4,253.75 was sent to Temple University to close out this project.

702-A A check in the amount of $4,000.00 was received from Temple University, representing the estimated refund after Dr. Niden's transfer to Drew Postgraduate Medical School effective June 1, 1973. This money was deposited and a check drawn to Drew to aid Dr. Niden in starting up the project at that institution.

752R1S Erik Skinhøj, M.D. A supplement in the amount of $256.00 was approved to pay for reprints from the July issue of the Journal of Applied Physiology.

763-A John W. Parker, M.D. Permission was granted to carry forward the unexpended balance of $117.24 to 763-AR1.

763-AR1 Permission was granted to transfer $800.00 from Supplies to Salaries.

Permission was granted to extend this project from July 1 to December 31, 1973.

787-A Gary D. Friedman, M.D. An unexpended balance of $5,182.65 remained from 787R1 and this was deducted from the present grant authorization of $101,100.00, making the final authorization $95,917.35.

808R1 Allen B. Cohen, M.D. An unexpended balance of $2,305.94 was returned and deposited.

814R1 Una Smith, Ph.D. Permission was granted to transfer $400.00 from Supplies to Travel.

864 Theodore Slotkin, Ph.D. Permission was granted to transfer $3,025.00 from Supplies to Equipment.

877-S Herbert B. Herscowitz, Ph.D. Travel expenses for Dr. Herscowitz of $119.23 were approved from Washington, D.C. to the CTR offices.

10035450B9

Source: https://www.industrydocuments.ucsf.edu/docs/zjdm0000

Contract 3-B IIT Research Institute. After having been cancelled as of March 31, 1973 and funding requirements settled as of that date, a balance of $12,398.32 remained which was cancelled.

Contract 6-B After having been cancelled as of March 31, 1973 and funding requirements settled as of that date, a balance of $16,168.44 remained which was cancelled.

The following authorizations were approved at a staff meeting on August 2, 1973:

709-CS Lucio Severi, M.D. This project was extended for the months of September and October 1973 in a pro rata amount of $2,500.00 so that the grantee can continue his project until a decision as to his application is made at the SAB meeting in October.

836-AS Walter B. Essman, Ph.D., M.D. This project was extended for the month of October 1973 in a pro rata amount of $3,334.00 so that the grantee can continue his project until a decision as to his application is made at the SAB meeting in October.

839RlS Edwin R. Fisher, M.D. This project was extended for the month of October 1973 in a pro rata amount of $2,108.00 so that the grantee can continue his project until a decision as to his renewal application is made at the SAB meeting in October.

868S Herbert McKennis Jr., Ph.D. This project was extended for the month of October 1973 in a pro rata amount of $5,000.00 so that the grantee can continue his project until a decision as to his renewal application is made at the SAB meeting in October.

875S Sheldon C. Sommers, M.D. This project was extended for the month of October 1973 in a pro rata amount of $7,539.50 so that the grantee can continue his project until a decision as to his renewal application is made at the SAB meeting in October.

877S Herbert B. Herscowitz, Ph.D. This project was extended for the month of October 1973 in a pro rata amount of $2,719.00 so that the grantee can continue his project until a decision as to his renewal application is made at the SAB meeting in October.

The following authorizations were approved:

Contract 2-E Microbiological Associates Incorporated. $115.10 This amount was expended for testing five available inbred lines at Lakeview Hamster Colony for different aryl hydrocarbon hydroxylase levels. This contract was approved for $157,000.00 at the Planning Committee meeting on December 8, 1972. Of this amount, a pro rata award of $25,000.00 was authorized covering the period February 1 through March 31, 1973. The total contract as finally signed was for $150,000.00 covering the period February 1, 1973 through January 31, 1974.

Contract 17 William E. Benedict, M.D. While traveling on contract business, Dr. Benedict incurred expenses totaling $548.92 and was reimbursed.

1003545090

Source: https://www.industrydocuments.ucsf.edu/docs/zjnn0000

4. The following renewal applications were recommended for approval, subject to the determination by the Scientific Director as to priority and the amount to be funded:

709-CR1 Lucio Severi, M.D. $19,948.00

814R2 Una Smith Ryan, Ph.D. $35,373.00 Terminal.

836-AR1 Walter B. Essman, Ph.D., M.D. $40,000.00

839R2 Edwin R. Fisher, M.D. $24,978.00 Terminal.

843R2 A. Clifford Barger, M.D. $50,000.00 Terminal.

868R1 Herbert McKennis Jr., Ph.D. $60,000.00 Terminal.

869R1 Ronald P. Rubin, Ph.D. $16,675.00

875R1 Harry L. Ioachim, M.D. (S. C. Sommers, M.D.) $79,815.00 (See paragraphs 14 and 15, treating the request as two projects, one a supplement to 875 [Sommers] and one a new number 945 [Ioachim].)

877R1 Herbert B. Herscowitz, Ph.D. $29,940.00

878R1 Paul Hamosh, M.D. $28,265.00

889R1 Timothy J. Regan, M.D. $45,500.00

891R1 Dr. Georg B. Neurath $44,850.00

5. The following new applications were recommended for approval subject to the determination of the Scientific Director as to priority and the amount to be funded:

467-C Thomas C. Westfall, Ph.D. $21,953.00

572-C Jay A. Levy, M.D. $49,118.00

642-C Leonide Goldstein, D.Sc. $33,350.00

702-C Albert H. Niden, M.D. $25,618.00

741-B Joseph M. Lauweryns, M.D., Ph.D. $24,556.00

787-B Gary D. Friedman, M.D. $99,440.00

841-A Charles Mittman, M.D. $36,608.00

864-A Theodore A. Slotkin, Ph.D. $13,346.00

906 Robert E. Brooks, Ph.D. $14,658.00

909 John A. Rosecrans, Ph.D. $17,730.00

914 Michael E. Lamm, M.D. $34,672.00

10035091

Source: https://www.industrydocuments.ucsf.edu/docs/zjdm0000

915 Edward Bresnick, Ph.D. $40,650.00

917 Patricia M. Hudgins, Ph.D. $22,400.00

918 H. Fred Downey, Ph.D. $15,290.00

923 Guenther Boden, M.D. $36,206.00

928 Daniel B. Rifkin, Ph.D. $36,077.00

929 Edward Leete, Ph.D. $23,709.00

933 Charles R. Shaw, M.D. $35,000.00

935 William H. Fishman, Ph.D. $62,853.00

936 Branislav Vidic, Sc.D. $40,738.00

937 Carroll E. Cross, M.D. $44,650.00

6. The following new application was deferred pending a site visit and receipt of additional information:

912 Sam G. McClugage, Ph.D. $38,094.00

7. The following new applications were rated for disapproval:

603-C Shirley L. Kauffman, M.D. $30,521.00

815-B John R. Esterly, M.D. $34,482.00

833-A A. Stanley Weltman, Ph.D. $58,386.00

888 T. J. Yang, Ph.D. $43,692.00

904 David Aperion, Ph.D. $50,496.00

905 Edward P. Domino, M.D. $52,885.00

907 Ines Mandl, Ph.D. $38,717.00

908 Sanford E. Leeds, M.D. $56,485.00

910 James M. Ramsey, M.D. $10,859.00

911 Wistar Institute $83,075.00

913 Anthony J. Sbarra, Ph.D. $65,100.00

916 Robert A. Goldstein, M.D. $29,900.00

919 John R. Daniels, M.D. $51,216.00

920 William F. Benedict, M.D. $25,700.00

921 Theodore N. Finley, M.D. $90,712.00

922 Joseph C. Arcos, M.D. $49,738.00

10035450 92

Source: https://www.industrydocuments.ucsf.edu/docs/jdmb0000

924 John C. Houck, Ph.D. $36,098.00

925 L. G. S. Rao, Ph.D. $3,950.00

926 Budh Dev Bhagat, Ph.D. $31,360.00

927 David J. Wilson, Ph.D. $8,973.00

930 Andrew Sivak, Ph.D. $54,838.00

931 Gerald M. Rosen, Ph.D. $12,156.00

932 W. LeRoy Heinrichs, M.D., Ph.D. $73,108.00

934 Wendell M. Stanley, Ph.D. $65,420.00

8. The following proposal for contract renewal was recommended for approval subject to the determination of the Scientific Director as to priority and the amount to be funded:

Contract 2-F Microbiological Associates Incorporated $137,500.00 for a period of eleven months.

9. The following proposal for contract continuation was rated for disapproval:

Contract 5-D Bio-Research Consultants, Inc. $499,000.00

10. The following proposal for contract continuation was deferred and the Executive Committee of the Advisory Board was authorized to act as necessary after a staff commentary and recommendation are distributed to the entire Board and each member has had an opportunity to express an opinion:

Contract 4-D Bio-Research Institute Incorporated $157,000.00

11. The Board recommended that the staff undertake to contract with Richard A. Lerner, M.D. to expand the work he is now conducting (Contract 16) at a cost not to exceed $60,000.00 for one year beginning January 1, 1974.

12. The status of twin studies was reviewed by Dr. Gardner who described his recent meeting with Dr. Rune Cederlöf and Dr. Lars Friberg in Stockholm, Sweden. The Board recommended approval of up to a total of $50,000.00 for the staff to apply to:

1. Preliminary costs to cover arrangements for further exploratory work by Dr. Cederlöf and his associates at The Karolinska Institute, and

2. Underwriting an organizational meeting of approximately 25 people, representing twin registries and data from various places to be held during the week of December 10, 1973 in Miami Beach.

1003545093

Source: https://www.industrydocuments.ucsf.edu/docs/zjdm0000

13. The next meeting of the Scientific Advisory Board was scheduled for March 13-14-15, 1974 in Scottsdale, Arizona. The staff was requested to invite Dr. Carrie Whitmire and Dr. Frank Dixon to attend.

14. Subsequent to the meeting, of the renewal applications recommended for approval and referred to in paragraph 4, the Scientific Director determined that the following should be funded in the respective amounts indicated:

709-CS2	Lucio Severi, M.D. $7,500.00 less $2,500.00 (709-CS). (See page 3.) Terminal.
814R2	Una Smith Ryan, Ph.D. $35,373.00 Terminal.
836-AR1	Walter B. Essman, Ph.D., M.D. $44,000.00 less $3,334.00 (836-AS). (See page 3.)
839R1S2	Edwin R. Fisher, M.D. $12,489.00 less $2,108.00 (839R1S). (See page 3.) Terminal.
843R2	A. Clifford Barger, M.D. $50,000.00 Terminal.
868S2	Herbert McKennis Jr., Ph.D. $30,000.00 less $5,000.00 (868S). (See page 3.) Terminal.
869R1	Ronald P. Rubin, Ph.D. $16,675.00 Terminal.
875S2	Sheldon C. Sommers, M.D. $15,079.00 supplement for the months of November and December 1973. (See 875R1, application by Ioachim and Sommers referred to in paragraph 4.)
877R1	Herbert B. Herscowitz, Ph.D. $29,940.00 less $2,719.00 (877S). (See page 3.)
878R1	Paul Hamosh, M.D. $28,265.00
889R1	Timothy J. Regan, M.D. $45,500.00
891R1	Dr. Georg B. Neurath $44,850.00

15. Subsequent to the meeting, of the new applications recommended for approval and referred to in paragraph 5, the Scientific Director determined that the following should be funded in the respective amounts indicated:

467-C	Thomas C. Westfall, Ph.D. $21,953.00
572-C	Jay A. Levy, M.D. $40,000.00
642-C	Leonid Goldstein, D.Sc. $33,350.00 Terminal.
702-C	Albert H. Niden, M.D. $25,618.00 No assurance of further support.
741-B	Joseph M. Lauweryns, M.D., Ph.D. $24,556.00 No assurance of further support.

1003545094

Source: https://www.industrydocuments.ucsf.edu/docs/zjdm0000

787-B Gary D. Friedman, M.D. $99,440.00

841-A Charles Mittman, M.D. $32,238.00 Terminal.

864-A Theodore A. Slotkin, Ph.D. $13,346.00 No assurance of further support.

906 Robert E. Brooks, Ph.D. $14,658.00 No assurance of further support.

909 John A. Rosecrans, Ph.D. $17,730.00

914 Michael E. Lamm, M.D. $34,672.00

918 H. Fred Downey, Ph.D. $15,290.00

923 Guenther Boden, M.D. $36,206.00

928 Daniel B. Rifkin, Ph.D. $36,077.00

929 Edward Leete, Ph.D. $23,709.00 No assurance of further support.

933 Charles R. Shaw, M.D. $35,000.00

936 Branislav Vidic, S.D. $36,256.00

937 Carroll E. Cross, M.D. $44,650.00

945 Harry L. Ioachim, M.D. $40,000.00 No assurance of further support. (See 875R1, application by Ioachim and Sommers, referred to in paragraph 4.)

16. Subsequent to the meeting, of the new applications recommended for approval and referred to in paragraph 5, the Scientific Director determined that the following should be deferred pending further information:

935 William H. Fishman, Ph.D. $36,256.00

17. Subsequent to the meeting, of the contract proposals recommended for approval and referred to in paragraph 8, the Scientific Director determined that the following should be funded in the respective amount indicated:

Contract 2-F Microbiological Associates Incorporated $137,500.00 for a period of eleven months.

10035450 95

Source: https://www.industrydocuments.ucsf.edu/docs/zjdm0000